Amgen Files for FDA Approval of Aranesp
- Share via
Amgen Inc. filed for government approval to market Aranesp, its next-generation anemia drug, for treatment of chemotherapy-induced anemia, a potential $4.7-billion market. The application is expected to be approved a year from now.
Analysts expect off-label use of Aranesp in advance of FDA action because its price compares favorably with that of Procrit, a first-generation anemia treatment marketed by Johnson & Johnson.
A weekly dose of Aranesp, as suggested by Amgen-sponsored research involving cancer patients, costs about $400 compared with $445 for Procrit.
The federal agency this week approved Aranesp to treat anemic kidney disease patients. In that market, because of dosing differences, Aranesp has no price advantage over Procrit or Amgen’s first-generation treatment, Epogen.
Amgen shares rose $1.05 to close at$59 on Nasdaq.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
